Perforación gastrointestinal secundaria a tratamiento con bevacizumab en carcinoma de cuello uterino

Elisabet Nogué-Pujadas; Clara Lezcano-Rubio; David López-Sisamón; Margarita Romeo-Marín

doi:10.7399/fh.2015.39.6.9651

Perforación gastrointestinal secundaria a tratamiento con bevacizumab en carcinoma de cuello uterino

Elisabet Nogué-Pujadas, Clara Lezcano-Rubio, David López-Sisamón, Margarita Romeo-Marín

Resumen

Palabras clave

Texto completo:

PDF

Referencias

BC Cancer Agency Cancer Drug Manual. Bevacizumab monograph. Vancouver: BC Cancer Agency; 2013 [Acceso el 20 de Abril de 2015]. Disponible en: http://www.bccancer.bc.ca

Penson RT, Huang HQ, Wenzei LB, Monk BJ, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomized, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015;16:301-11.

Borofsky SE, Levine MS, Rubesin SE, Tanyi JL, Chu CS, Lev-Toaff AS. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom Imaging. 2013;38:265-72.

Qi W-X, Shen Z, Tang L-N, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014;70:893-906.

DOI: http://dx.doi.org/10.7399%2Ffh.2015.39.6.9651